Cambridge, UK
o2h Ventures is pleased to announce another strategic SEIS investment in Vesynta. Vesynta is revolutionising precision drug dosing by integrating drug monitoring services with quantitative pharmacology to ensure better regimen safety and efficacy.
Vesynta overcomes the limitations of the “one size fits all” approach prevalent in drug label formation, which overlooks the unique ways different patients process drugs, leading to reduced quality of life, increased care costs, and sub-optimal drug development. 1st-generation solutions lack integration, scalability, and speed, limiting access to clinical insight and data quality. The result is a broken feedback loop and “trial and error” dose selection continuing to target maximum tolerance, over maximum efficaciousness.
Vesynta’s Dosologic platform is a software-based technology supporting personalised dosing guided by pharmacological measurements, applicable across a range of diseases including cancer and infectious disease. This approach can support dose optimisations for approved drugs in clinical practice, in addition to accelerating optimised drug labels during the clinical trial process.
Vesynta are also developing applications to ensure better sample and data quality, facilitating improved data integration and higher quality predictions to optimise model-informed clinical insights to prevent toxicity and recommend better treatment.
Committed to promoting health equity for underserved and special patient populations, Vesynta has received significant funding and research support from partner organisations including the National Institute of Health Research, LifeArc Ventures, Sheffield Teaching Hospital NHS Trust, Newcastle University, and Innovate UK.
Sunil Shah, CEO of o2h Ventures, said:
An exciting venture which graduated from KQ Labs in London. A clear problem that is well documented is that individuals require a different dose of medicine for optimal effectiveness. We have seen so many different solutions to solve this, however, Vesynta has taken both an offline monitoring and assessment coupled with intelligent data analytics to solve this. It’s a straight-forward, scalable solution and Jugal seems well equipped and driven to execute on this plan.
Dr Jugal Suthar, CEO of Vesynta, said:
We are delighted with o2h’s support, where seed funds are aligned and matched against current grant-funded projects – DosoLogic and CheckPoint. The round accelerates development of our core decision support platform to be in the hands of users in 2025, whilst also driving commercial partnerships with drug developers seeking to expand labels to special patient populations. This financial support is further endorsement of Vesynta’s progress and approach in delivering a high-impact mission of making dose selection more personalised for improved outcomes.
About Vesynta
Vesynta is a data-guided precision dosing company. They personalise dose selection, to maximise therapeutic potential, making drug regimens safer, more effective and personalised. They combine patient monitoring data with machine-learning simulations to enable model-informed label expansion in clinical trials and dose individualisation in healthcare. Their people aspire to improve health outcomes and experiences for patients, by reducing life-limiting side effects and variability in response caused by “one-size-fits-all” dose selection approaches. Their data-guided approach supports smarter clinical decisions and personalised dosing regimes tailored to the individual’s pharmacology, ensuring the best possible treatment and care.
About o2h Ventures
The o2h Ventures ‘Human Health’ SEIS and EIS funds make tax-efficient investments in Pre-Seed and seed-stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tools offerings throughout the biotech ecosystem, and we spur the creation of software & artificial intelligence that will change healthcare.
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.
For more information or to invest in the fund, please visit www.o2hventures.com
Media Contact:
Juhi Shah
Marketing Manager
